Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study.

Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8703941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1615-5947 (Electronic) Linking ISSN: 08905096 NLM ISO Abbreviation: Ann Vasc Surg Subsets: MEDLINE

Publication: <2007->: Netherlands : Elsevier
Original Publication: Detroit : [Published by Expansion scientifique française for Annals of Vascular Surgery, Inc. and Association pour la promotion de la chirurgie vasculaire, Paris, c1986-

Femoral Artery*/diagnostic imaging ; Femoral Artery*/physiopathology ; Rivaroxaban*/administration & dosage ; Rivaroxaban*/adverse effects ; Aspirin*/administration & dosage ; Aspirin*/adverse effects ; Peripheral Arterial Disease*/therapy ; Peripheral Arterial Disease*/physiopathology ; Peripheral Arterial Disease*/diagnostic imaging ; Angioplasty, Balloon*/instrumentation ; Angioplasty, Balloon*/adverse effects ; Popliteal Artery*/physiopathology ; Popliteal Artery*/diagnostic imaging ; Platelet Aggregation Inhibitors*/administration & dosage ; Platelet Aggregation Inhibitors*/adverse effects ; Vascular Patency* ; Recurrence* ; Coated Materials, Biocompatible* ; Factor Xa Inhibitors*/administration & dosage ; Factor Xa Inhibitors*/adverse effects; Humans ; Male ; Female ; Retrospective Studies ; Aged ; Middle Aged ; Treatment Outcome ; Time Factors ; Stents ; Vascular Access Devices ; Risk Factors ; Aged, 80 and over ; Dual Anti-Platelet Therapy

Background: After drug-coated balloon (DCB) treatment of the femoropopliteal artery in-stent restenosis (ISR), a certain proportion of patients also experience target lesion restenosis. The purpose of this study was to explore the efficacy and safety of rivaroxaban combined with aspirin in the treatment of ISR after DCB intervention.
Methods: Patients who underwent DCB treatment for ISR after femoropopliteal artery intervention at our center from March 2017 to February 2022 were included consecutively. According to the drug treatment after DCB intervention of ISR, the patients were divided into rivaroxaban and aspirin group (RA Group) and dual antiplatelet therapy (DAPT) group. The outcomes of 2 groups during the 12-month follow-up after DCB intervention were compared.
Results: A total of 92 patients were included in final analysis, with 43 in RA group and 49 in DAPT group. During 12-month follow-up, a total of 15 cases of recurrent ISR were detected, and the recurrence rate of ISR and clinically driven target lesion revascularization in the RA group were lower than those in the DAPT group (P < 0.05). The vascular patency rate in the RA group was higher than that in the DAPT group at 6 and 12 months of follow-up (P < 0.05). During the follow-up, there were no adverse events such as death, myocardial infarction, stroke, amputation, or major bleeding, and only a total of 5 cases of minor bleeding occurred.
Conclusions: Compared with the standard DAPT regimen, rivaroxaban combined with aspirin can safely improve the follow-up outcome after DCB for femoropopliteal ISR.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)

9NDF7JZ4M3 (Rivaroxaban)
R16CO5Y76E (Aspirin)
0 (Platelet Aggregation Inhibitors)
0 (Coated Materials, Biocompatible)
0 (Factor Xa Inhibitors)

Date Created: 20240716 Date Completed: 20240914 Latest Revision: 20240914

20240916

10.1016/j.avsg.2024.05.031

39013487